retatrutide dosing clinical trial Reta data & — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP Lilly's triple agonist, retatrutide, delivered

Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications increasingly prescribed for type 2 diabetes management and, more recently, weight management

The solution should be clear and colorless

France, N

Preliminary data published in June 2023 also suggests that GLP-1 drugs 'could modulate crucial pathways in the pathogenesis of inflammatory bowel disease (IBD), such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity' (Arvanitakis, Theocharis, Popovic